Econstudentlog

Imported Plant Diseases

I found myself debating whether or not I should read Lewis, Petrovskii, and Potts’ text The Mathematics Behind Biological Invasions a while back, but at the time I in the end decided that it would simply be too much work to justify the potential payoff – so instead of reading the book, I decided to just watch the above lecture and leave it at that. This lecture is definitely a very poor textbook substitute, and I was strongly debating whether or not to blog it because it just isn’t very good; the level of coverage is very low. Which is sad, because some of the diseases discussed in the lecture – like e.g. wheat leaf rust – are really important and worth knowing about. One of the important points made in the lecture is that in the context of potential epidemics, it can be difficult to know when and how to intervene because of the uncertainty involved; early action may be the more efficient choice in terms of resource use, but the earlier you intervene, the less certain will be the intervention payoff and the less you’ll know about stuff like transmission patterns (…would outbreak X ever really have spread very wide if we had not intervened? We don’t observe the counterfactual…). Such aspects of course are not only relevant to plant-diseases, and the lecture also contains other basic insights from epidemiology which apply to other types of disease – but if you’ve ever opened a basic epidemiology text you’ll know all these things already.

May 22, 2017 Posted by | Biology, Botany, Ecology, Epidemiology, Lectures | Leave a comment

Out of this World: A history of Structure in the Universe

This lecture is much less technical than were the last couple of lectures I posted, and if I remember correctly it’s aimed at a general audience (…the sort of ‘general audience’ that attends IAS lectures, but even so…). The lecture itself is quite short, only roughly 35 minutes long, but there’s a long Q&A session afterwards.

May 21, 2017 Posted by | Astronomy, Lectures, Physics | Leave a comment

Words

Sciolism, amative, hypocorism, leiotrichouslatitudinariancircumlocutionary, daedal, ceruse, wimple, doyen, fuscous, jorum, groupuscule, gelid, hadal, palfrey, malum, cachou, fellmonger, susurrus.

Zeteticeirenicon, dystocia, vicereine, brachiation, odalisque, daglock, galumph, plantain, insufflation, marquetry, névé, samite, pangram, whisk, hamiform, addeem, oeillade, daggle, teratophilia.

Boffin, paraph, girandole, stramineouscusp, telishment, lenition, paludous, phoresy, foramen, zymurgy, pinion, clusivity, gnomon, enallage, zymogram, autopoiesis, bradyseism, appurtenant, dealation.

Peen, chamfer, siphonapterology, onomastics, stridulate, whinging, irrorate, amnion, pectination, sturt, anthelminthic, arrhinia, aprosopia, viscidity, periotic, constat, muffler, ostosis, petrichor, scelidate.

Thalassochorykex, engastration, braw, urbicolous, armillary, clanger, crith, enteron, mullion, quag, hooch, enounce, congé, bdelygmia, catenative, falx, cotyledon, egret, pericyte.

May 20, 2017 Posted by | language | Leave a comment

The Mathematical Challenge of Large Networks

This is another one of the aforementioned lectures I watched a while ago, but had never got around to blogging:

If I had to watch this one again, I’d probably skip most of the second half; it contains highly technical coverage of topics in graph theory, and it was very difficult for me to follow (but I did watch it to the end, just out of curiosity).

The lecturer has put up a ~500 page publication on these and related topics, which is available here, so if you want to know more that’s an obvious place to go have a look. A few other relevant links to stuff mentioned/covered in the lecture:
Szemerédi regularity lemma.
Graphon.
Turán’s theorem.
Quantum graph.

May 19, 2017 Posted by | Lectures, Mathematics, Statistics | Leave a comment

Hydrodynamical Simulations of Galaxy Formation: Progress, Pitfalls, and Promises

“This calculation was relatively expensive, about 19 million CPU hours were spent on it.”

….

Posts including only one lecture is a recent innovation here on the blog as I have in the past bundled lectures so that a lecture post would include at least 2 or 3 lectures, but I am starting to come around to the idea that these new types of posts are a good idea. I have been going over some old lectures I’ve watched in the past recently, and it turns out that there are quite a few lectures I never got around to blogging; I have mentioned before how the 3 lectures per post format was likely suboptimal, in the sense that they tended to lead to lectures never being covered e.g. because of the long time lag between watching a lecture and blogging it (in the case of book blogging I tend to be much more likely to spend my time covering books I read recently, rather than books I read a while ago, and the same dynamic goes for lectures), and I think this impression is now confirmed.

As some of the lectures I’ll be covering in posts like these in the future are lectures I watched a long time ago my coverage will probably be limited to the actual lectures and the comments I wrote down when I first watched the lecture in question. I don’t want to add a few big lecture posts to just get rid of the backlog, mostly because this blog is obviously not nearly as active as it used to be, and adding single-lecture posts dropwise is an easy (…low-effort) and convenient way for me to keep the blog at least somewhat active. What I wrote down in my comments about the lecture above when I watched it, aside from the quote above, is that considering the very high-level physics included it was sort of surprising to me that the lecture was not so technical as to not be worth watching – but it wasn’t. You’ll certainly not understand all of it, but it’s interesting stuff.

May 18, 2017 Posted by | Astronomy, Lectures, Physics | Leave a comment

A few diabetes papers of interest

i. Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes.

“The Joint National Committee and American Diabetes Association guidelines currently recommend a blood pressure (BP) target of <140/90 mmHg for all adults with diabetes, regardless of type (13). However, evidence used to support this recommendation is primarily based on data from trials of type 2 diabetes (46). The relationship between BP and adverse outcomes in type 1 and type 2 diabetes may differ, given that the type 1 diabetes population is typically much younger at disease onset, hypertension is less frequently present at diagnosis (3), and the basis for the pathophysiology and disease complications may differ between the two populations.

Prior prospective cohort studies (7,8) of patients with type 1 diabetes suggested that lower BP levels (<110–120/70–80 mmHg) at baseline entry were associated with a lower risk of adverse renal outcomes, including incident microalbuminuria. In one trial of antihypertensive treatment in type 1 diabetes (9), assignment to a lower mean arterial pressure (MAP) target of <92 mmHg (corresponding to ∼125/75 mmHg) led to a significant reduction in proteinuria compared with a MAP target of 100–107 mmHg (corresponding to ∼130–140/85–90 mmHg). Thus, it is possible that lower BP (<120/80 mmHg) reduces the risk of important renal outcomes, such as proteinuria, in patients with type 1 diabetes and may provide a synergistic benefit with intensive glycemic control on renal outcomes (1012). However, fewer studies have examined the association between BP levels over time and the risk of more advanced renal outcomes, such as stage III chronic kidney disease (CKD) or end-stage renal disease (ESRD)”.

“The primary objective of this study was to determine whether there is an association between lower BP levels and the risk of more advanced diabetic nephropathy, defined as macroalbuminuria or stage III CKD, within a background of different glycemic control strategies […] We included 1,441 participants with type 1 diabetes between the ages of 13 and 39 years who had previously been randomized to receive intensive versus conventional glycemic control in the Diabetes Control and Complications Trial (DCCT). The exposures of interest were time-updated systolic BP (SBP) and diastolic BP (DBP) categories. Outcomes included macroalbuminuria (>300 mg/24 h) or stage III chronic kidney disease (CKD) […] During a median follow-up time of 24 years, there were 84 cases of stage III CKD and 169 cases of macroalbuminuria. In adjusted models, SBP in the 2 (95% CI 1.05–1.21), and a 1.04 times higher risk of ESRD (95% CI 0.77–1.41) in adjusted Cox models. Every 10 mmHg increase in DBP was associated with a 1.17 times higher risk of microalbuminuria (95% CI 1.03–1.32), a 1.15 times higher risk of eGFR decline to 2 (95% CI 1.04–1.29), and a 0.80 times higher risk of ESRD (95% CI 0.47–1.38) in adjusted models. […] Because these data are observational, they cannot prove causation. It remains possible that subtle kidney disease may lead to early elevations in BP, and we cannot rule out the potential for reverse causation in our findings. However, we note similar trends in our data even when imposing a 7-year lag between BP and CKD ascertainment.”

CONCLUSIONS A lower BP (<120/70 mmHg) was associated with a substantially lower risk of adverse renal outcomes, regardless of the prior assigned glycemic control strategy. Interventional trials may be useful to help determine whether the currently recommended BP target of 140/90 mmHg may be too high for optimal renal protection in type 1 diabetes.”

It’s important to keep in mind when interpreting these results that endpoints like ESRD and stage III CKD are not the only relevant outcomes in this setting; even mild-stage kidney disease in diabetics significantly increase the risk of death from cardiovascular disease, and a substantial proportion of patients may die from cardiovascular disease before reaching a late-stage kidney disease endpoint (here’s a relevant link).

Identifying Causes for Excess Mortality in Patients With Diabetes: Closer but Not There Yet.

“A number of epidemiological studies have quantified the risk of death among patients with diabetes and assessed the causes of death (26), with highly varying results […] Overall, the studies to date have confirmed that diabetes is associated with an increased risk of all-cause mortality, but the magnitude of this excess risk is highly variable, with the relative risk ranging from 1.15 to 3.15. Nevertheless, all studies agree that mortality is mainly attributable to cardiovascular causes (26). On the other hand, studies of cancer-related death have generally been lacking despite the diabetes–cancer association and a number of plausible biological mechanisms identified to explain this link (8,9). In fact, studies assessing the specific causes of noncardiovascular death in diabetes have been sparse. […] In this issue of Diabetes Care, Baena-Díez et al. (10) report on an observational study of the association between diabetes and cause-specific death. This study involved 55,292 individuals from 12 Spanish population cohorts with no prior history of cardiovascular disease, aged 35 to 79 years, with a 10-year follow-up. […] This study found that individuals with diabetes compared with those without diabetes had a higher risk of cardiovascular death, cancer death, and noncardiovascular noncancer death with similar estimates obtained using the two statistical approaches. […] Baena-Díez et al. (10) showed that individuals with diabetes have an approximately threefold increased risk of cardiovascular mortality, which is much higher than what has been reported by recent studies (5,6). While this may be due to the lack of adjustment for important confounders in this study, there remains uncertainty regarding the magnitude of this increase.”

“[A]ll studies of excess mortality associated with diabetes, including the current one, have produced highly variable results. The reasons may be methodological. For instance, it may be that because of the wide range of age in these studies, comparing the rates of death between the patients with diabetes and those without diabetes using a measure based on the ratio of the rates may be misleading because the ratio can vary by age [it almost certainly does vary by age, US]. Instead, a measure based on the difference in rates may be more appropriate (16). Another issue relates to the fact that the studies include patients with longstanding diabetes of variable duration, resulting in so-called prevalent cohorts that can result in muddled mortality estimates since these are necessarily based on a mix of patients at different stages of disease (17). Thus, a paradigm change may be in order for future observational studies of diabetes and mortality, in the way they are both designed and analyzed. With respect to cancer, such studies will also need to tease out the independent contribution of antidiabetes treatments on cancer incidence and mortality (1820). It is thus clear that the quantification of the excess mortality associated with diabetes per se will need more accurate tools.”

iii. Risk of Cause-Specific Death in Individuals With Diabetes: A Competing Risks Analysis. This is the paper some of the results of which were discussed above. I’ll just include the highlights here:

RESULTS We included 55,292 individuals (15.6% with diabetes and overall mortality of 9.1%). The adjusted hazard ratios showed that diabetes increased mortality risk: 1) cardiovascular death, CSH = 2.03 (95% CI 1.63–2.52) and PSH = 1.99 (1.60–2.49) in men; and CSH = 2.28 (1.75–2.97) and PSH = 2.23 (1.70–2.91) in women; 2) cancer death, CSH = 1.37 (1.13–1.67) and PSH = 1.35 (1.10–1.65) in men; and CSH = 1.68 (1.29–2.20) and PSH = 1.66 (1.25–2.19) in women; and 3) noncardiovascular noncancer death, CSH = 1.53 (1.23–1.91) and PSH = 1.50 (1.20–1.89) in men; and CSH = 1.89 (1.43–2.48) and PSH = 1.84 (1.39–2.45) in women. In all instances, the cumulative mortality function was significantly higher in individuals with diabetes.

CONCLUSIONS Diabetes is associated with premature death from cardiovascular disease, cancer, and noncardiovascular noncancer causes.”

“Summary

Diabetes is associated with premature death from cardiovascular diseases (coronary heart disease, stroke, and heart failure), several cancers (liver, colorectal, and lung), and other diseases (chronic obstructive pulmonary disease and liver and kidney disease). In addition, the cause-specific cumulative mortality for cardiovascular, cancer, and noncardiovascular noncancer causes was significantly higher in individuals with diabetes, compared with the general population. The dual analysis with CSH and PSH methods provides a comprehensive view of mortality dynamics in the population with diabetes. This approach identifies the individuals with diabetes as a vulnerable population for several causes of death aside from the traditionally reported cardiovascular death.”

iv. Disability-Free Life-Years Lost Among Adults Aged ≥50 Years With and Without Diabetes.

RESEARCH DESIGN AND METHODS Adults (n = 20,008) aged 50 years and older were followed from 1998 to 2012 in the Health and Retirement Study, a prospective biannual survey of a nationally representative sample of adults. Diabetes and disability status (defined by mobility loss, difficulty with instrumental activities of daily living [IADL], and/or difficulty with activities of daily living [ADL]) were self-reported. We estimated incidence of disability, remission to nondisability, and mortality. We developed a discrete-time Markov simulation model with a 1-year transition cycle to predict and compare lifetime disability-related outcomes between people with and without diabetes. Data represent the U.S. population in 1998.

RESULTS From age 50 years, adults with diabetes died 4.6 years earlier, developed disability 6–7 years earlier, and spent about 1–2 more years in a disabled state than adults without diabetes. With increasing baseline age, diabetes was associated with significant (P < 0.05) reductions in the number of total and disability-free life-years, but the absolute difference in years between those with and without diabetes was less than at younger baseline age. Men with diabetes spent about twice as many of their remaining years disabled (20–24% of remaining life across the three disability definitions) as men without diabetes (12–16% of remaining life across the three disability definitions). Similar associations between diabetes status and disability-free and disabled years were observed among women.

CONCLUSIONS Diabetes is associated with a substantial reduction in nondisabled years, to a greater extent than the reduction of longevity. […] Using a large, nationally representative cohort of Americans aged 50 years and older, we found that diabetes is associated with a substantial deterioration of nondisabled years and that this is a greater number of years than the loss of longevity associated with diabetes. On average, a middle-aged adult with diabetes has an onset of disability 6–7 years earlier than one without diabetes, spends 1–2 more years with disability, and loses 7 years of disability-free life to the condition. Although other nationally representative studies have reported large reductions in complications (9) and mortality among the population with diabetes in recent decades (1), these studies, akin to our results, suggest that diabetes continues to have a substantial impact on morbidity and quality of remaining years of life.”

v. Association Between Use of Lipid-Lowering Therapy and Cardiovascular Diseases and Death in Individuals With Type 1 Diabetes.

“People with type 1 diabetes have a documented shorter life expectancy than the general population without diabetes (1). Cardiovascular disease (CVD) is the main cause of the excess morbidity and mortality, and despite advances in management and therapy, individuals with type 1 diabetes have a markedly elevated risk of cardiovascular events and death compared with the general population (2).

Lipid-lowering treatment with hydroxymethylglutaryl-CoA reductase inhibitors (statins) prevents major cardiovascular events and death in a broad spectrum of patients (3,4). […] We hypothesized that primary prevention with lipid-lowering therapy (LLT) can reduce the incidence of cardiovascular morbidity and mortality in individuals with type 1 diabetes. The aim of the study was to examine this in a nationwide longitudinal cohort study of patients with no history of CVD. […] A total of 24,230 individuals included in 2006–2008 NDR with type 1 diabetes without a history of CVD were followed until 31 December 2012; 18,843 were untreated and 5,387 treated with LLT [Lipid-Lowering Therapy] (97% statins). The mean follow-up was 6.0 years. […] Hazard ratios (HRs) for treated versus untreated were as follows: cardiovascular death 0.60 (95% CI 0.50–0.72), all-cause death 0.56 (0.48–0.64), fatal/nonfatal stroke 0.56 (0.46–0.70), fatal/nonfatal acute myocardial infarction 0.78 (0.66–0.92), fatal/nonfatal coronary heart disease 0.85 (0.74–0.97), and fatal/nonfatal CVD 0.77 (0.69–0.87).

CONCLUSIONS This observational study shows that LLT is associated with 22–44% reduction in the risk of CVD and cardiovascular death among individuals with type 1 diabetes without history of CVD and underlines the importance of primary prevention with LLT to reduce cardiovascular risk in type 1 diabetes.”

vi. Prognostic Classification Factors Associated With Development of Multiple Autoantibodies, Dysglycemia, and Type 1 Diabetes—A Recursive Partitioning Analysis.

“In many prognostic factor studies, multivariate analyses using the Cox proportional hazards model are applied to identify independent prognostic factors. However, the coefficient estimates derived from the Cox proportional hazards model may be biased as a result of violating assumptions of independence. […] RPA [Recursive Partitioning Analysis] classification is a useful tool that could prioritize the prognostic factors and divide the subjects into distinctive groups. RPA has an advantage over the proportional hazards model in identifying prognostic factors because it does not require risk factor independence and, as a nonparametric technique, makes no requirement on the underlying distributions of the variables considered. Hence, it relies on fewer modeling assumptions. Also, because the method is designed to divide subjects into groups based on the length of survival, it defines groupings for risk classification, whereas Cox regression models do not. Moreover, there is no need to explicitly include covariate interactions because of the recursive splitting structure of tree model construction.”

“This is the first study that characterizes the risk factors associated with the transition from one preclinical stage to the next following a recommended staging classification system (9). The tree-structured prediction model reveals that the risk parameters are not the same across each transition. […] Based on the RPA classification, the subjects at younger age and with higher GAD65Ab [an important biomarker in the context of autoimmune forms of diabetes, US – here’s a relevant link] titer are at higher risk for progression to multiple positive autoantibodies from a single autoantibody (seroconversion). Approximately 70% of subjects with a single autoantibody were positive for GAD65Ab, much higher than for insulin autoantibody (24%) and IA-2A [here’s a relevant link – US] (5%). Our study results are consistent with those of others (2224) in that seroconversion is age related. Previous studies in infants and children at an early age have shown that progression from single to two or more autoantibodies occurs more commonly in children 25). The subjects ≤16 years of age had almost triple the 5-year risk compared with subjects >16 years of age at the same GAD65Ab titer level. Hence, not all individuals with a single islet autoantibody can be thought of as being at low risk for disease progression.”

“This is the first study that identifies the risk factors associated with the timing of transitions from one preclinical stage to the next in the development of T1D. Based on RPA risk parameters, we identify the characteristics of groups with similar 5-year risks for advancing to the next preclinical stage. It is clear that individuals with one or more autoantibodies or with dysglycemia are not homogeneous with regard to the risk of disease progression. Also, there are differences in risk factors at each stage that are associated with increased risk of progression. The potential benefit of identifying these groups allows for a more informed discussion of diabetes risk and the selective enrollment of individuals into clinical trials whose risk more appropriately matches the potential benefit of an experimental intervention. Since the risk levels in these groups are substantial, their definition makes possible the design of more efficient trials with target sample sizes that are feasible, opening up the field of prevention to additional at-risk cohorts. […] Our results support the evidence that autoantibody titers are strong predictors at each transition leading to T1D development. The risk of the development of multiple autoantibodies was significantly increased when the GAD65Ab titer level was elevated, and the risk of the development of dysglycemia was increased when the IA-2A titer level increased. These indicate that better risk prediction on the timing of transitions can be obtained by evaluating autoantibody titers. The results also suggest that an autoantibody titer should be carefully considered in planning prevention trials for T1D in addition to the number of positive autoantibodies and the type of autoantibody.”

May 17, 2017 Posted by | Studies, Medicine, Diabetes, Statistics, Immunology, Nephrology | Leave a comment

Today’s Landscape of Pharmaceutical Research in Cancer

It’s been a while since I watched this lecture so I don’t remember the details very well, but I usually add notes in my bookmarks when I watch lectures so that I know what details to include in my comments here on the blog, and I have added the details from the bookmark notes below.

It is a short lecture, the lecture itself lasts only roughly 30 minutes; it doesn’t really start until roughly the 9 minutes and 30 seconds mark, and it finishes around the 44 min mark (the rest is Q&A – I skipped some of the introduction, but watched the Q&A). The lecture is not very technical, I think the content is perfectly understandable also to people without a medical background. One data point from the lecture which I thought worth including in these comments is this: According to Sigal, “roughly 30 per cent of the biopharmaceutical industry’s portfolio … is focused on research in oncology.”

May 17, 2017 Posted by | Cancer/oncology, Immunology, Lectures, Medicine, Pharmacology | Leave a comment

Quotes

i. “The rare individual who has learned to govern himself is too fed up with the labor of it to want to govern anybody else.” (Henry S. Haskins)

ii. “I prefer true but imperfect knowledge, even if it leaves much indetermined and unpredictable, to a pretence of exact knowledge that is likely to be false.” (Friedrich Hayek)

iii. “The history of science shows that the progress of science has constantly been hampered by the tyrannical influence of certain conceptions that finally came to be considered as dogma. For this reason, it is proper to submit periodically to a very searching examination, principles that we have come to assume without any more discussion.” (Louis de Broglie)

iv. “The circle of knowledge commences close round a man and thence stretches out concentrically.” (Johann Heinrich Pestalozzi)

v. “It is easier to forgive an Enemy than to forgive a Friend.” (William Blake)

vi. “Life is not long, and too much of it must not pass in idle deliberation how it shall be spent.” (Samuel Johnson)

vii. “For an idea ever to be fashionable is ominous, since it must afterwards be always old-fashioned.” (George Santayana)

viii. “Give a small boy a hammer, and he will find that everything he encounters needs pounding. It comes as no particular surprise to discover that a scientist formulates problems in a way which requires for their solution just those techniques in which he himself is especially skilled.” (Abraham Kaplan)

ix. “Friendship is like money, easier made than kept.” (Samuel Butler)

x. “With most men, unbelief in one thing springs from blind belief in another.” (Georg Christoph Lichtenberg)

xi. “To many people virtue consists chiefly in repenting faults, not in avoiding them.” (-ll-)

xii. “A man has virtues enough if, on account of them, he deserves forgiveness for his faults.” (-ll-)

xiii. “What is a committee? A group of the unwilling, picked from the unfit, to do the unnecessary” (Richard Harkness)

xiv. “There is nothing so easily made offensive as good reasoning; and men of clear logical minds, if not gifted at the same time with tact, make more enemies than men with bad hearts and unsound understandings.” (Arthur Helps)

xv. “Nothing so sharpens the thought process as writing down one’s arguments. Weaknesses overlooked in oral discussion become painfully obvious on the written page.” (Hyman G. Rickover)

xvi. “The outcome of any serious research can only be to make two questions grow where only one grew before.” (Thorstein Veblen)

xvii. “A celebrity is one who is known to many persons he is glad he doesn’t know.” (Henry Louis Mencken)

xviii. “Harpo, she’s a lovely person. She deserves a good husband. Marry her before she finds one.” (Harpo Marx, Harpo Speaks!)

xix. “A minimum of comfort is necessary for the practice of virtue.” (Patrice Lumumba)

xx. “Blind commitment to a theory is not an intellectual virtue: it is an intellectual crime.” (Imre Lakatos)

May 16, 2017 Posted by | Quotes/aphorisms | Leave a comment

Quantifying tradeoffs between fairness and accuracy in online learning

From a brief skim of this paper, which is coauthored by the guy giving this lecture, it looked to me like it covers many of the topics discussed in the lecture. So if you’re unsure as to whether or not to watch the lecture (…or if you want to know more about this stuff after you’ve watched the lecture) you might want to have a look at that paper. Although the video is long for a single lecture I would note that the lecture itself lasts only approximately one hour; the last 10 minutes are devoted to Q&A.

May 12, 2017 Posted by | Computer science, Economics, Lectures, Mathematics | Leave a comment

A few diabetes papers of interest

A couple of weeks ago I decided to cover some of the diabetes articles I’d looked at and bookmarked in the past, but there were a lot of articles and I did not get very far. This post will cover some more of these articles I had failed to cover here despite intending to do so at some point. Considering that I these days relatively regularly peruse e.g. the Diabetes Care archives I am thinking of making this sort of post a semi-regular feature of the blog.

i. Association Between Diabetes and Hippocampal Atrophy in Elderly Japanese: The Hisayama Study.

“A total of 1,238 community-dwelling Japanese subjects aged ≥65 years underwent brain MRI scans and a comprehensive health examination in 2012. Total brain volume (TBV), intracranial volume (ICV), and hippocampal volume (HV) were measured using MRI scans for each subject. We examined the associations between diabetes-related parameters and the ratios of TBV to ICV (an indicator of global brain atrophy), HV to ICV (an indicator of hippocampal atrophy), and HV to TBV (an indicator of hippocampal atrophy beyond global brain atrophy) after adjustment for other potential confounders.”

“The multivariable-adjusted mean values of the TBV-to-ICV, HV-to-ICV, and HV-to-TBV ratios were significantly lower in the subjects with diabetes compared with those without diabetes (77.6% vs. 78.2% for the TBV-to-ICV ratio, 0.513% vs. 0.529% for the HV-to-ICV ratio, and 0.660% vs. 0.676% for the HV-to-TBV ratio; all P < 0.01). These three ratios decreased significantly with elevated 2-h postload glucose (PG) levels […] Longer duration of diabetes was significantly associated with lower TBV-to-ICV, HV-to-ICV, and HV-to-TBV ratios. […] Our data suggest that a longer duration of diabetes and elevated 2-h PG levels, a marker of postprandial hyperglycemia, are risk factors for brain atrophy, particularly hippocampal atrophy.”

“Intriguingly, our findings showed that the subjects with diabetes had significantly lower mean HV-to-TBV ratio values, indicating […] that the hippocampus is predominantly affected by diabetes. In addition, in our subjects a longer duration and a midlife onset of diabetes were significantly associated with a lower HV, possibly suggesting that a long exposure of diabetes particularly worsens hippocampal atrophy.”

The reason why hippocampal atrophy is a variable of interest to these researchers is that hippocampal atrophy is a feature of Alzheimer’s Disease, and diabetics have an elevated risk of AD. This is incidentally far from the first study providing some evidence for the existence of potential causal linkage between impaired glucose homeostasis and AD (see e.g. also this paper, which I’ve previously covered here on the blog).

ii. A Population-Based Study of All-Cause Mortality and Cardiovascular Disease in Association With Prior History of Hypoglycemia Among Patients With Type 1 Diabetes.

“Although patients with T1DM may suffer more frequently from hypoglycemia than those with T2DM (8), very few studies have investigated whether hypoglycemia may also increase the risk of CVD (6,9,10) or death (1,6,7) in patients with T1DM; moreover, the results of these studies have been inconclusive (6,9,10) because of the dissimilarities in their methodological aspects, including their enrollment of populations with T1DM with different levels of glycemic control, application of different data collection methods, and adoption of different lengths of observational periods.”

“Only a few population-based studies have examined the potential cumulative effect of repeated severe hypoglycemia on all-cause mortality or CVD incidence in T1DM (9). The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study of T2DM found a weakly inverse association between the annualized number of hypoglycemic episodes and the risk of death (11,12). By contrast, some studies find that repeated hypoglycemia may be an aggravating factor to atherosclerosis in T1DM (13,14). Studies on the compromised sympathetic-adrenal reaction in patients with repeated hypoglycemia have been inconclusive regarding whether such a reaction may further damage intravascular coagulation and thrombosis (15) or decrease the vulnerability of these patients to adverse health outcomes (12).

Apart from the lack of information on the potential dose–gradient effect associated with severe hypoglycemic events in T1DM from population-based studies, the risks of all-cause mortality/CVD incidence associated with severe hypoglycemia occurring at different periods before all-cause mortality/CVD incidence have never been examined. In this study, we used the population-based medical claims of a cohort of patients with T1DM to examine whether the risks of all-cause mortality/CVD incidence are associated with previous episodes of severe hypoglycemia in different periods and whether severe hypoglycemia may pose a dose–gradient effect on the risks of all-cause mortality/CVD incidence.”

“Two nested case-control studies with age- and sex-matched control subjects and using the time-density sampling method were performed separately within a cohort of 10,411 patients with T1DM in Taiwan. The study enrolled 564 nonsurvivors and 1,615 control subjects as well as 743 CVD case subjects and 1,439 control subjects between 1997 and 2011. History of severe hypoglycemia was identified during 1 year, 1–3 years, and 3–5 years before the occurrence of the study outcomes.”

“Prior severe hypoglycemic events within 1 year were associated with higher risks of all-cause mortality and CVD (adjusted OR 2.74 [95% CI 1.96–3.85] and 2.02 [1.35–3.01], respectively). Events occurring within 1–3 years and 3–5 years before death were also associated with adjusted ORs of 1.94 (95% CI 1.39–2.71) and 1.68 (1.15–2.44), respectively. Significant dose–gradient effects of severe hypoglycemia frequency on mortality and CVD were observed within 5 years. […] we found that a greater frequency of severe hypoglycemia occurring 1 year before death was significantly associated with a higher OR of all-cause mortality (1 vs. 0: 2.45 [95% CI 1.65–3.63]; ≥2 vs. 0: 3.49 [2.01–6.08], P < 0.001 for trend). Although the strength of the association was attenuated, a significant dose–gradient effect still existed for severe hypoglycemia occurring in 1–3 years (P < 0.001 for trend) and 3–5 years (P < 0.015 for trend) before death. […] Exposure to repeated severe hypoglycemic events can lead to higher risks of mortality and CVD.”

“Our findings are supported by two previous studies that investigated atherosclerosis risk in T1DM (13,14). The DCCT/EDIC project reported that the prevalence of coronary artery calcification, an established atherosclerosis marker, was linearly correlated with the incidence rate of hypoglycemia on the DCCT stage (14). Giménez et al. (13) also demonstrated that repeated episodes of hypoglycemia were an aggravating factor for preclinical atherosclerosis in T1DM. […] The mechanism of hypoglycemia that predisposes to all-cause mortality/CVD incidence remains unclear.”

iii. Global Estimates on the Number of People Blind or Visually Impaired by Diabetic Retinopathy: A Meta-analysis From 1990 to 2010.

“On the basis of previous large-scale population-based studies and meta-analyses, diabetic retinopathy (DR) has been recognized as one of the most common and important causes for visual impairment and blindness (1–19). These studies in general showed that DR was the leading cause of blindness globally among working-aged adults and therefore has a significant socioeconomic impact (20–22).”

“A previous meta-analysis (21) summarizing 35 studies with more than 20,000 patients with diabetes estimated a prevalence of any DR of 34.6%, of diabetic macular edema of 6.8%, and of vision-threating DR of 10.2% within the diabetes population. […] Yau et al. (21) estimated that ∼93 million people had some DR and 28 million people had sight-threatening stages of DR. However, this meta-analysis did not address the prevalence of visual impairment and blindness due to DR and thus the impact of DR on the general population. […] We therefore conducted the present meta-analysis of all available population-based studies performed worldwide within the last two decades as part of the Global Burden of Disease Study 2010 (GBD) to estimate the number of people affected by blindness and visual impairment.”

“DR [Diabetic Retinopathy] ranks as the fifth most common cause of global blindness and of global MSVI [moderate and severe vision impairment] (25). […] this analysis estimates that, in 2010, 1 out of every 39 blind people had blindness due to DR and 1 out of every 52 people had visual impairment due to DR. […] Globally in 2010, out of overall 32.4 million blind and 191 million visually impaired people, 0.8 million were blind and 3.7 million were visually impaired because of DR, with an alarming increase of 27% and 64%, respectively, spanning the two decades from 1990 to 2010. DR accounted for 2.6% of all blindness in 2010 and 1.9% of all MSVI worldwide, increasing from 2.1% and 1.3%, respectively, in 1990. […] The number of persons with visual impairment due to DR worldwide is rising and represents an increasing proportion of all blindness/MSVI causes. Age-standardized prevalence of DR-related blindness/MSVI was higher in sub-Saharan Africa and South Asia.”

“Our data suggest that the percentage of blindness and MSVI attributable to DR was lower in low-income regions with younger populations than in high-income regions with older populations. There are several reasons that may explain this observation. First, low-income societies may have a higher percentage of unoperated cataract or undercorrected refractive error–related blindness and MSVI (25), which is probably related to access to visual and ocular health services. Therefore, the proportional increase in blindness and MSVI attributable to DR may be rising because of the decreasing proportion attributable to cataract (25) as a result of the increasing availability of cataract surgery in many parts of the world (29) during the past decade. Improved visualization of the fundus afforded by cataract surgery should also improve the detection of DR. The increase in the percentage of global blindness caused by DR within the last two decades took place in all world regions except Western Europe and high-income North America where there was a slight decrease. This decrease may reflect the effect of intensified prevention and treatment of DR possibly in part due to the introduction of intravitreal injections of steroids and anti-VEGF (vascular endothelial growth factor) drugs (30,31).

Second, in regions with poor medical infrastructure, patients with diabetes may not live long enough to experience DR (32). This reduces the number of patients with diabetes, and, furthermore, it reduces the number of patients with DR-related vision loss. Studies in the literature have reported that the prevalence of severe DR decreased from 1990 to 2010 (21) while the prevalence of diabetes simultaneously increased (27), which implies a reduction in the prevalence of severe DR per person with diabetes. […] Third, […] younger populations may have a lower prevalence of diabetes (33). […] Therefore, considering further economic development in rural regions, improvements in medical infrastructure, the general global demographic transition to elderly populations, and the association between increasing economic development and obesity, we project the increase in the proportion of DR-related blindness and MSVI to continue to rise in the future.”

iv. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1c Targets?

“In setting hemoglobin A1c (HbA1c) targets, physicians must consider individualized risks and benefits of tight glycemic control (1,2) by recognizing that the risk-benefit ratio may become unfavorable in certain patients, including the elderly and/or those with multiple comorbidities (3,4). Customization of treatment goals based on patient characteristics is poorly understood, partly due to insufficient data on physicians’ decisions in setting targets. We used the National Health and Nutrition Examination Survey (NHANES) to analyze patient-reported HbA1c targets set by physicians and to test whether targets are correlated with patient characteristics.”

“we did not find any evidence that U.S. physicians systematically consider important patient-specific information when selecting the intensity of glycemic control. […] the lack of variation with patient characteristics suggests overreliance on a general approach, without consideration of individual variation in the risks and benefits (or patient preference) of tight control.”

v. Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes.

“This study evaluated associations among cardiovascular autonomic neuropathy (CAN), female sexual dysfunction (FSD), and urinary incontinence (UI) in women with type I diabetes mellitus (T1DM). […] We studied 580 women with T1DM in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC).”

“At EDIC year 17, FSD was observed in 41% of women and UI in 30%. […] We found that CAN was significantly more prevalent among women with FSD and/or UI, because 41% of women with FSD and 44% with UI had positive measures of CAN compared with 30% without FSD and 38% without UI at EDIC year 16/17. We also observed bivariate associations between FSD and several measures of CAN […] In long-standing T1DM, CAN may predict development of FSD and may be a useful surrogate for generalized diabetic autonomic neuropathy.”

“Although autonomic dysfunction has been considered an important factor in the etiology of many diabetic complications, including constipation, exercise intolerance, bladder dysfunction, erectile dysfunction, orthostatic hypotension, and impaired neurovascular function, our study is among the first to systematically demonstrate a link between CAN and FSD in a large cohort of well-characterized patients with T1DM (14).”

vi. Correlates of Medication Adherence in the TODAY Cohort of Youth With Type 2 Diabetes.

“A total of 699 youth 10–17 years old with recent-onset type 2 diabetes and ≥80% adherence to metformin therapy for ≥8 weeks during a run-in period were randomized to receive one of three treatments. Participants took two study pills twice daily. Adherence was calculated by pill count from blister packs returned at visits. High adherence was defined as taking ≥80% of medication; low adherence was defined as taking <80% of medication.”

“In this low socioeconomic cohort, high and low adherence did not differ by sex, age, family income, parental education, or treatment group. Adherence declined over time (72% high adherence at 2 months, 56% adherence at 48 months, P < 0.0001). A greater percentage of participants with low adherence had clinically significant depressive symptoms at baseline (18% vs. 12%, P = 0.0415). No adherence threshold predicted the loss of glycemic control. […] Most pediatric type 1 diabetes studies (5–7) consistently document a correlation between adherence and race, ethnicity, and socioeconomic status, and studies of adults with type 2 diabetes (8,9) have documented that depressed patients are less adherent to their diabetes regimen. There is a dearth of information in the literature regarding adherence to medication in pediatric patients with type 2 diabetes.”

“In the cohort, the presence of baseline clinically significant depressive symptoms was associated with subsequent lower adherence. […] The TODAY cohort demonstrated deterioration in study medication adherence over time, irrespective of treatment group assignment. […] Contrary to expectation, demographic factors (sex, race-ethnicity, household income, and parental educational level) did not predict medication adherence. The lack of correlation with these factors in the TODAY trial may be explained by the limited income and educational range of the families in the TODAY trial. Nearly half of the families in the TODAY trial had an annual income of <$25,000, and, for over half of the families, the highest level of parental education was a high school degree or lower. In addition, our run-in criteria selected for more adherent subjects. All subjects had to have >80% adherence to M therapy for ≥8 weeks before they could be randomized. This may have limited variability in medication adherence postrandomization. It is also possible that selecting for more adherent subjects in the run-in period also selected for subjects with a lower frequency of depressive symptoms.”

“In the TODAY trial, baseline clinically significant depressive symptoms were more prevalent in the lower-adherence group, suggesting that regular screening for depressive symptoms should be undertaken to identify youth who were at high risk for poor medication adherence. […] Studies in adults with type 2 diabetes (2328) consistently report that depressed patients are less adherent to their diabetes regimen and experience more physical complications of diabetes. Identifying youth who are at risk for poor medication adherence early in the course of disease would make it possible to provide support and, if needed, specific treatment. Although we were not able to determine whether the treatment of depressive symptoms changed adherence over time, our findings support the current guidelines for psychosocial screening in youth with diabetes (29,30).”

vii. Increased Risk of Incident Chronic Kidney Disease, Cardiovascular Disease, and Mortality in Patients With Diabetes With Comorbid Depression.

Another depression-related paper, telling another part of the story. If depressed diabetics are less compliant/adherent, which seems – as per the above study – to be the case both in the context of the adult and pediatric patient population, then you might also expect this reduced compliance/adherence to ‘translate’ into this group having poorer metabolic control, and thus be at higher risk of developing microvascular complications such as nephropathy. This seems to be what we observe, at least according to the findings of this study:

“It is not known if patients with diabetes with depression have an increased risk of chronic kidney disease (CKD). We examined the association between depression and incident CKD, mortality, and incident cardiovascular events in U.S. veterans with diabetes.”

“Among a nationally representative prospective cohort of >3 million U.S. veterans with baseline estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m2, we identified 933,211 patients with diabetes. Diabetes was ascertained by an ICD-9-CM code for diabetes, an HbA1c >6.4%, or receiving antidiabetes medication during the inclusion period. Depression was defined by an ICD-9-CM code for depression or by antidepressant use during the inclusion period. Incident CKD was defined as two eGFR levels 2 separated by ≥90 days and a >25% decline in baseline eGFR.”

“Depression was associated with 20% higher risk of incident CKD (adjusted hazard ratio [aHR] and 95% CI: 1.20 [1.19–1.21]). Similarly, depression was associated with increased all-cause mortality (aHR and 95% CI: 1.25 [1.24–1.26]). […] The presence of depression in patients with diabetes is associated with higher risk of developing CKD compared with nondepressed patients.”

It’s important to remember that the higher reported eGFRs in the depressed patient group may not be important/significant, and they should not be taken as an indication of relatively better kidney function in this patient population – especially in the type 2 context, the relationship between eGFR and kidney function is complicated. I refer to Bakris et al.‘s text on these topics for details (blog coverage here).

May 6, 2017 Posted by | Cardiology, Diabetes, Medicine, Nephrology, Neurology, Psychology, Studies | Leave a comment

Standing on the Shoulders of Mice: Aging T-cells

Most of the lecture is not about mice, but rather about stuff like this and this (both papers are covered in the lecture). I’ve read about related topics before (see e.g this), but if you haven’t some parts of the lecture will probably be too technical for you to follow.

May 3, 2017 Posted by | Papers, Medicine, Cancer/oncology, Genetics, Lectures, Immunology, Cardiology | Leave a comment

Words

Almost all the words included in this post are words I encountered while reading the Flashman novels Flashman and the Mountain of Light, Flash for Freedom!, and Flashman and the Redskins. Almost all the words are words I have not included in similar posts in the past, but I decided to include a few words (2 or 3 words, something like that) I already included in similar posts in the past because I like those words and the fact that I had taken notice of them while reading these novels indicates to me that they haven’t yet stuck in my mind the way I’d like them to do; I usually only mark out words with which I’m either unfamiliar or words the meaning of which I have trouble remembering.

The post includes 6 segments of 20 words/concepts each.

Duff. Coparcener. Chunter. Haver. Sop. Purdah. Bedewing. Paynim. Conniptions. Pap. Tiffin. Aigrette. Whippet. Grandee. Caparison. Howdah. Mahout. Malediction. Tipple. Slantendicular.

Collogue. Hocussing. Sobersided/sobersides. Grog. Ramage. Hutment. Peradventure. Truckle. Caracole. Hustings. Gamester. Barracoon. Bowsprit. Gorget. Midge. Mumchance. Kurbash. Mudge. Unchancy. Mizzenmast/mizzen.

Wiseacre. Cully. SibilantHummock. Gloaming. Clew. Bestride. Dragoman. Lanyard. Binnacle. Stevedore. Corn pone/pone. Bawd. Spavin. Plaintiff. Wickiup. Julep. Holystone. Crimp. Melodeon.

Bitumen. Reticule. Roustabout. Teamster (Interestingly what this word means seems to have changed over time. In the Flashman setting the word is used to describe someone who’s handling teams of slaves; i.e. a slave driver). Serape. Crupper. Stockman. Carter. Clodpole. Tenderfoot. Chevron. Doss. Coonskin. Roué. Bight. Ferrule. Bodkin. Pelf. Pother. Ford.

Concourse. Dixie. Tobyman. Kedgeree. Prepossess. Rivet. Clubbable. Bower. Pottle. Clog. Waft. Lariat. Bargee. Gallus. Navvy. Papoose. Levee. Minatory. Wend. Statuary.

Fustian. Blatherskite. Escritoire. Twanging. Tippet. Wanton. Convivial. Blandishment. Quirt. Coulee. Guidon. Sorrel. Arrant. Contumelious. Depilation. Magnate. Vatic. Grimalkin. Manciple. Banns.

May 2, 2017 Posted by | Books, language | Leave a comment

Quotes (and a brief administrative note)

(Brief admin note: I have been doing a bit of ‘spring cleaning’ on the blog these last few days, as I have been trying to improve upon the category system I currently use. If people have been bothered by old posts of mine showing up in their feeds this is the reason. The changes I have made will make it easier for me to find stuff I might be looking for in the future, but as the changes might also make it easier for other people reading along to find stuff here on the blog in which they might be interested I figured I should mention the fact that these changes have been made to the readers as well. The primary change to the category system which has been made is that I have increased the number of sub-topics used in the context of coverage of topics dealing with biology and medicine. I have also increased the number of topics displayed in the category cloud in the sidebar.)

i. “I do not greatly care whether I have been right or wrong on any point, but I care a good deal about knowing which of the two I have been.” (Samuel Butler)

ii. “Our minds want clothes as much as our bodies.” (-ll-)

iii. “Some like to understand what they believe in. Others like to believe in what they understand” (Stanisław Jerzy Lec)

iv. “The struggle for existence holds as much in the intellectual as in the physical world. A theory is a species of thinking, and its right to exist is coextensive with its power of resisting extinction by its rivals.” (Thomas Henry Huxley)

v. “We should treat our minds, that is, ourselves, as innocent and ingenuous children, whose guardians we are, and be careful what objects and what subjects we thrust on their attention.” (Henry David Thoreau)

vi. “Where there is no bread, there is no philosophy.” (Avram Davidson)

vii. “The price of training is always a certain “trained incapacity”: the more we know how to do something, the harder it is to learn to do it differently.” (Abraham Kaplan)

viii. “We are endowed with genes which code out our reaction to beavers and otters, maybe our reaction to each other as well. We are stamped with stereotyped, unalterable patterns of response, ready to be released. And the behavior released in us, by such confrontations, is, essentially, a surprised affection. It is compulsory behavior and we can avoid it only by straining with the full power of our conscious minds, making up conscious excuses all the way. Left to ourselves, mechanistic and autonomic, we hanker for friends.” (Lewis Thomas)

ix. “I have always had a bad memory, as far back as I can remember.” (-ll-)

x. “It isn’t what people think that’s important, but the reason they think what they think.” (Eugène Ionesco)

xi. “The relationship between commitment and doubt is by no means an antagonistic one. Commitment is healthiest when it is not without doubt but in spite of doubt.” (Rollo May)

xii. “People will resist information unless the price of not knowing it greatly exceeds the price of learning it.” (Calvin Mooers)

xiii. “Beware of averages. The average person has one breast and one testicle.” (Dixy Lee Ray)

xiv. “I saw an advertisement the other day for the secret of life. It said “The secret of life can be yours for twenty-five shillings. Send to Secret of Life Institute, Willesden.” So I wrote away, seemed a good bargain, secret of life, twenty-five shillings. And I got a letter back saying, “If you think you can get the secret of life for twenty-five shillings, you don’t deserve to have it. Send fifty shillings for the secret of life.”” (Peter Cook)

xv. “We believe this to be the work of thieves, and I’ll tell you why. The whole pattern is very reminiscent of past robberies where we have found thieves to be involved. The tell-tale loss of property — that’s one of the signs we look for.” (-ll-)

xvi. “I’ve been reading a very interesting book recently. It’s called The Universe and All That Surrounds It by T J Bleendreeble. It’s an extremely good book about it. It’s about seventy pages long, so it’s fairly comprehensive about the whole thing and it’s fairly interesting. Bleendreeble specialises in the universe. He doesn’t branch out much beyond that. But he’s quite interested in this limited field.” (-ll-)

xvii. “It is the great glory of the quest for human knowledge that, while making some small contribution to that quest, we can also continue to learn and to take pleasure in learning.” (William Alfred Fowler)

xviii. “In science, it is not speed that is the most important. It is the dedication, the commitment, the interest and the will to know something and to understand it — these are the things that come first.” (Eugene Wigner)

xix. “It is not enough to be in the right place at the right time. You should also have an open mind at the right time.” (Paul Erdős)

xx. “If you want to change the way people respond to you, change the way you respond to people.” (Timothy Leary)

April 27, 2017 Posted by | meta, Quotes/aphorisms | Leave a comment

A few diabetes papers of interest

1. Cognitive Dysfunction in Older Adults With Diabetes: What a Clinician Needs to Know. I’ve talked about these topics before here on the blog (see e.g. these posts on related topics), but this is a good summary article. I have added some observations from the paper below:

“Although cognitive dysfunction is associated with both type 1 and type 2 diabetes, there are several distinct differences observed in the domains of cognition affected in patients with these two types. Patients with type 1 diabetes are more likely to have diminished mental flexibility and slowing of mental speed, whereas learning and memory are largely not affected (8). Patients with type 2 diabetes show decline in executive function, memory, learning, attention, and psychomotor efficiency (9,10).”

“So far, it seems that the risk of cognitive dysfunction in type 2 diabetes may be influenced by glycemic control, hypoglycemia, inflammation, depression, and macro- and microvascular pathology (14). The cumulative impact of these conditions on the vascular etiology may further decrease the threshold at which cognition is affected by other neurological conditions in the aging brain. In patients with type 1 diabetes, it seems as though diabetes has a lesser impact on cognitive dysfunction than those patients with type 2 diabetes. […] Thus, the cognitive decline in patients with type 1 diabetes may be mild and may not interfere with their functionality until later years, when other aging-related factors become important. […] However, recent studies have shown a higher prevalence of cognitive dysfunction in older patients (>60 years of age) with type 1 diabetes (5).”

“Unlike other chronic diseases, diabetes self-care involves many behaviors that require various degrees of cognitive pliability and insight to perform proper self-care coordination and planning. Glucose monitoring, medications and/or insulin injections, pattern management, and diet and exercise timing require participation from different domains of cognitive function. In addition, the recognition, treatment, and prevention of hypoglycemia, which are critical for the older population, also depend in large part on having intact cognition.

The reason a clinician needs to recognize different domains of cognition affected in patients with diabetes is to understand which self-care behavior will be affected in that individual. […] For example, a patient with memory problems may forget to take insulin doses, forget to take medications/insulin on time, or forget to eat on time. […] Cognitively impaired patients using insulin are more likely to not know what to do in the event of low blood glucose or how to manage medication on sick days (34). Patients with diminished mental flexibility and processing speed may do well with a simple regimen but may fail if the regimen is too complex. In general, older patients with diabetes with cognitive dysfunction are less likely to be involved in diabetes self-care and glucose monitoring compared with age-matched control subjects (35). […] Other comorbidities associated with aging and diabetes also add to the burden of cognitive impairment and its impact on self-care abilities. For example, depression is associated with a greater decline in cognitive function in patients with type 2 diabetes (36). Depression also can independently negatively impact the motivation to practice self-care.”

“Recently, there is an increasing discomfort with the use of A1C as a sole parameter to define glycemic goals in the older population. Studies have shown that A1C values in the older population may not reflect the same estimated mean glucose as in the younger population. Possible reasons for this discrepancy are the commonly present comorbidities that impact red cell life span (e.g., anemia, uremia, renal dysfunction, blood transfusion, erythropoietin therapy) (45,46). In addition, A1C level does not reflect glucose excursions and variability. […] Thus, it is prudent to avoid A1C as the sole measure of glycemic goal in this population. […] In patients who need insulin therapy, simplification, also known as de-intensification of the regimen, is generally recommended in all frail patients, especially if they have cognitive dysfunction (37,49). However, the practice has not caught up with the recommendations as shown by large observational studies showing unnecessary intensive control in patients with diabetes and dementia (50–52).”

“With advances in the past few decades, we now see a larger number of patients with type 1 diabetes who are aging successfully and facing the new challenges that aging brings. […] Patients with type 1 diabetes are typically proactive in their disease management and highly disciplined. Cognitive dysfunction in these patients creates significant distress for the first time in their lives; they suddenly feel a “lack of control” over the disease they have managed for many decades. The addition of autonomic dysfunction, gastropathy, or neuropathy may result in wider glucose excursions. These patients are usually more afraid of hyperglycemia than hypoglycemia — both of which they have managed for many years. However, cognitive dysfunction in older adults with type 1 diabetes has been found to be associated with hypoglycemic unawareness and glucose variability (5), which in turn increases the risk of severe hypoglycemia (54). The need for goal changes to avoid hypoglycemia and accept some hyperglycemia can be very difficult for many of these patients.”

2. Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013.

“From 2006 to 2013, use increased for metformin (from 47.6 to 53.5%), dipeptidyl peptidase 4 inhibitors (0.5 to 14.9%), and insulin (17.1 to 23.0%) but declined for sulfonylureas (38.8 to 30.8%) and thiazolidinediones (28.5 to 5.6%; all P < 0.001). […] The overall rate of severe hypoglycemia remained the same (1.3 per 100 person-years; P = 0.72), declined modestly among the oldest patients (from 2.9 to 2.3; P < 0.001), and remained high among those with two or more comorbidities (3.2 to 3.5; P = 0.36). […] During the recent 8-year period, the use of glucose-lowering drugs has changed dramatically among patients with T2DM. […] The use of older classes of medications, such as sulfonylureas and thiazolidinediones, declined. During this time, glycemic control of T2DM did not improve in the overall population and remained poor among nearly a quarter of the youngest patients. Rates of severe hypoglycemia remained largely unchanged, with the oldest patients and those with multiple comorbidities at highest risk. These findings raise questions about the value of the observed shifts in drug utilization toward newer and costlier medications.”

“Our findings are consistent with a prior study of drug prescribing in U.S. ambulatory practice conducted from 1997 to 2012 (2). In that study, similar increases in DPP-4 inhibitor and insulin analog prescribing were observed; these changes were accompanied by a 61% increase in drug expenditures (2). Our study extends these findings to drug utilization and demonstrates that these increases occurred in all age and comorbidity subgroups. […] In contrast, metformin use increased only modestly between 2006 and 2013 and remained relatively low among older patients and those with two or more comorbidities. Although metformin is recommended as first-line therapy (26), it may be underutilized as the initial agent for the treatment of T2DM (27). Its use may be additionally limited by coexisting contraindications, such as chronic kidney disease (28).”

“The proportion of patients with a diagnosis of diabetes who did not fill any glucose-lowering medications declined slightly (25.7 to 24.1%; P < 0.001).”

That is, one in four people who had a diagnosis of type 2 diabetes were not taking any prescription drugs for their health condition. I wonder how many of those people have read wikipedia articles like this one

“When considering treatment complexity, the use of oral monotherapy increased slightly (from 24.3 to 26.4%) and the use of multiple (two or more) oral agents declined (from 33.0 to 26.5%), whereas the use of insulin alone and in combination with oral agents increased (from 6.0 to 8.5% and from 11.1 to 14.6%, respectively; all P values <0.001).”

“Between 1987 and 2011, per person medical spending attributable to diabetes doubled (4). More than half of the increase was due to prescription drug spending (4). Despite these spending increases and greater utilization of newly developed medications, we showed no concurrent improvements in overall glycemic control or the rates of severe hypoglycemia in our study. Although the use of newer and more expensive agents may have other important benefits (44), further studies are needed to define the value and cost-effectiveness of current treatment options.”

iii. Among Low-Income Respondents With Diabetes, High-Deductible Versus No-Deductible Insurance Sharply Reduces Medical Service Use.

“Using the 2011–2013 Medical Expenditure Panel Survey, bivariate and regression analyses were conducted to compare demographic characteristics, medical service use, diabetes care, and health status among privately insured adult respondents with diabetes, aged 18–64 years (N = 1,461) by lower (<200% of the federal poverty level) and higher (≥200% of the federal poverty level) income and deductible vs. no deductible (ND), low deductible ($1,000/$2,400) (LD), and high deductible (>$1,000/$2,400) (HD). The National Health Interview Survey 2012–2014 was used to analyze differences in medical debt and delayed/avoided needed care among adult respondents with diabetes (n = 4,058) by income. […] Compared with privately insured respondents with diabetes with ND, privately insured lower-income respondents with diabetes with an LD report significant decreases in service use for primary care, checkups, and specialty visits (27%, 39%, and 77% lower, respectively), and respondents with an HD decrease use by 42%, 65%, and 86%, respectively. Higher-income respondents with an LD report significant decreases in specialty (28%) and emergency department (37%) visits.”

“The reduction in ambulatory visits made by lower-income respondents with ND compared with lower-income respondents with an LD or HD is far greater than for higher-income patients. […] The substantial reduction in checkup (preventive) and specialty visits by those with a lower income who have an HDHP [high-deductible health plan, US] implies a very different pattern of service use compared with lower-income respondents who have ND and with higher-income respondents. Though preventive visits require no out-of-pocket costs, reduced preventive service use with HDHPs is well established and might be the result of patients being unaware of this benefit or their concern about findings that could lead to additional expenses (31). Such sharply reduced service use by low-income respondents with diabetes may not be desirable. Patients with diabetes benefit from assessment of diabetes control, encouragement and reinforcement of behavior change and medication use, and early detection and treatment of diabetes complications or concomitant disease.”

iv. Long-term Mortality and End-Stage Renal Disease in a Type 1 Diabetes Population Diagnosed at Age 15–29 Years in Norway.

OBJECTIVE To study long-term mortality, causes of death, and end-stage renal disease (ESRD) in people diagnosed with type 1 diabetes at age 15–29 years.

RESEARCH DESIGN AND METHODS This nationwide, population-based cohort with type 1 diabetes diagnosed during 1978–1982 (n = 719) was followed from diagnosis until death, emigration, or September 2013. Linkages to the Norwegian Cause of Death Registry and the Norwegian Renal Registry provided information on causes of death and whether ESRD was present.

RESULTS During 30 years’ follow-up, 4.6% of participants developed ESRD and 20.6% (n = 148; 106 men and 42 women) died. Cumulative mortality by years since diagnosis was 6.0% (95% CI 4.5–8.0) at 10 years, 12.2% (10.0–14.8) at 20 years, and 18.4% (15.8–21.5) at 30 years. The SMR [standardized mortality ratio] was 4.4 (95% CI 3.7–5.1). Mean time from diagnosis of diabetes to ESRD was 23.6 years (range 14.2–33.5). Death was caused by chronic complications (32.2%), acute complications (20.5%), violent death (19.9%), or any other cause (27.4%). Death was related to alcohol in 15% of cases. SMR for alcohol-related death was 6.8 (95% CI 4.5–10.3), for cardiovascular death was 7.3 (5.4–10.0), and for violent death was 3.6 (2.3–5.3).

CONCLUSIONS The cumulative incidence of ESRD was low in this cohort with type 1 diabetes followed for 30 years. Mortality was 4.4 times that of the general population, and more than 50% of all deaths were caused by acute or chronic complications. A relatively high proportion of deaths were related to alcohol.”

Some additional observations from the paper:

“Studies assessing causes of death in type 1 diabetes are most frequently conducted in individuals diagnosed during childhood (17) or without evaluating the effect of age at diagnosis (8,9). Reports on causes of death in cohorts of patients diagnosed during late adolescence or young adulthood, with long-term follow-up, are less frequent (10). […] Adherence to treatment during this age is poor and the risk of acute diabetic complications is high (1316). Mortality may differ between those with diabetes diagnosed during this period of life and those diagnosed during childhood.”

“Mortality was between four and five times higher than in the general population […]. The excess mortality was similar for men […] and women […]. SMR was higher in the lower age bands — 6.7 (95% CI 3.9–11.5) at 15–24 years and 7.3 (95% CI 5.2–10.1) at 25–34 years — compared with the higher age bands: 3.7 (95% CI 2.7–4.9) at 45–54 years and 3.9 (95% CI 2.6–5.8) at 55–65 years […]. The Cox regression model showed that the risk of death increased significantly by age at diagnosis (HR 1.1; 95% CI 1.1–1.2; P < 0.001) and was eight to nine times higher if ESRD was present (HR 8.7; 95% CI 4.8–15.5; P < 0.0001). […] the underlying cause of death was diabetes in 57 individuals (39.0%), circulatory in 22 (15.1%), cancer in 18 (12.3%), accidents or intoxications in 20 (13.7%), suicide in 8 (5.5%), and any other cause in 21 (14.4%) […] In addition, diabetes contributed to death in 29.5% (n = 43) and CVD contributed to death in 10.9% (n = 29) of the 146 cases. Diabetes was mentioned on the death certificate for 68.2% of the cohort but for only 30.0% of the violent deaths. […] In 60% (88/146) of the cases the review committee considered death to be related to diabetes, whereas in 40% (58/146) the cause was unrelated to diabetes or had an unknown relation to diabetes. According to the clinical committee, acute complications caused death in 20.5% (30/146) of the cases; 20 individuals died as a result of DKA and 10 from hypoglycemia. […] Chronic complications caused the largest proportion of deaths (47/146; 32.2%) and increased with increasing duration of diabetes […]. Among individuals dying as a result of chronic complications (n = 47), CVD caused death in 94% (n = 44) and renal failure in 6% (n = 3). ESRD contributed to death in 22.7% (10/44) of those dying from CVD. Cardiovascular death occurred at mortality rates seven times higher than those in the general population […]. ESRD caused or contributed to death in 13 of 14 cases, when present.”

“Violence (intoxications, accidents, and suicides) was the leading cause of death before 10 years’ duration of diabetes; thereafter it was only a minor cause […] Insulin was used in two of seven suicides. […] According to the available medical records and autopsy reports, about 20% (29/146) of the deceased misused alcohol. In 15% (22/146) alcohol-related ICD-10 codes were listed on the death certificate (18% [19/106] of men and 8% [3/40] of women). In 10 cases the cause of death was uncertain but considered to be related to alcohol or diabetes […] The SMR for alcohol-related death was high when considering the underlying cause of death (5.0; 95% CI 2.5–10.0), and even higher when considering all alcohol-related ICD-10 codes listed on the death certificate (6.8; 95% CI 4.5–10.3). The cause of death was associated with alcohol in 21.8% (19/87) of those who died with less than 20 years’ diabetes duration. Drug abuse was noted on the death certificate in only two cases.”

“During follow-up, 33 individuals (4.6%; 22 men and 11 women) developed ESRD as a result of diabetic nephropathy. Mean time from diagnosis of diabetes to ESRD was 23.6 years (range 14.2–33.5 years). Cumulative incidence of ESRD by years since diagnosis of diabetes was 1.4% (95% CI 0.7–2.7) at 20 years and 4.8% (95% CI 3.4–6.9) at 30 years.”

“This study highlights three important findings. First, among individuals who were diagnosed with type 1 diabetes in late adolescence and early adulthood and had good access to health care, and who were followed for 30 years, mortality was four to five times that of the general population. Second, 15% of all deaths were associated with alcohol, and the SMR for alcohol-related deaths was 6.8. Third, there was a relatively low cumulative incidence of ESRD (4.8%) 30 years after the diagnosis of diabetes.

We report mortality higher than those from a large, population-based study from Finland that found cumulative mortality around 6% at 20 years’ and 15% at 30 years’ duration of diabetes among a population with age at onset and year of diagnosis similar to those in our cohort (10). The corresponding numbers in our cohort were 12% and 18%, respectively; the discrepancy was particularly high at 20 years. The SMR in the Finnish cohort was lower than that in our cohort (2.6–3.0 vs. 3.7–5.1), and those authors reported the SMR to be lower in late-onset diabetes (at age 15–29 years) compared with early-onset diabetes (at age 23). The differences between the Norwegian and Finnish data are difficult to explain since both reports are from countries with good access to health care and a high incidence of type 1 diabetes.”

However the reason for the somewhat different SMRs in these two reasonably similar countries may actually be quite simple – the important variable may be alcohol:

“Finland and Norway are appropriate to compare because they share important population and welfare characteristics. There are, however, significant differences in drinking levels and alcohol-related mortality: the Finnish population consumes more alcohol and the Norwegian population consumes less. The mortality rates for deaths related to alcohol are about three to four times higher in Finland than in Norway (30). […] The markedly higher SMR in our cohort can probably be explained by the lower mortality rates for alcohol-related mortality in the general population. […] In conclusion, the high mortality reported in this cohort with an onset of diabetes in late adolescence and young adulthood draws attention to people diagnosed during a vulnerable period of life. Both acute and chronic complications cause substantial premature mortality […] Our study suggests that increased awareness of alcohol-related death should be encouraged in clinics providing health care to this group of patients.”

April 23, 2017 Posted by | Diabetes, Economics, Epidemiology, Medicine, Nephrology, Neurology, Papers, Pharmacology, Psychology | Leave a comment

Biodemography of aging (IV)

My working assumption as I was reading part two of the book was that I would not be covering that part of the book in much detail here because it would simply be too much work to make such posts legible to the readership of this blog. However I then later, while writing this post, had the thought that given that almost nobody reads along here anyway (I’m not complaining, mind you – this is how I like it these days), the main beneficiary of my blog posts will always be myself, which lead to the related observation/notion that I should not be limiting my coverage of interesting stuff here simply because some hypothetical and probably nonexistent readership out there might not be able to follow the coverage. So when I started out writing this post I was working under the assumption that it would be my last post about the book, but I now feel sure that if I find the time I’ll add at least one more post about the book’s statistics coverage. On a related note I am explicitly making the observation here that this post was written for my benefit, not yours. You can read it if you like, or not, but it was not really written for you.

I have added bold a few places to emphasize key concepts and observations from the quoted paragraphs and in order to make the post easier for me to navigate later (all the italics below are on the other hand those of the authors of the book).

Biodemography is a multidisciplinary branch of science that unites under its umbrella various analytic approaches aimed at integrating biological knowledge and methods and traditional demographic analyses to shed more light on variability in mortality and health across populations and between individuals. Biodemography of aging is a special subfield of biodemography that focuses on understanding the impact of processes related to aging on health and longevity.”

“Mortality rates as a function of age are a cornerstone of many demographic analyses. The longitudinal age trajectories of biomarkers add a new dimension to the traditional demographic analyses: the mortality rate becomes a function of not only age but also of these biomarkers (with additional dependence on a set of sociodemographic variables). Such analyses should incorporate dynamic characteristics of trajectories of biomarkers to evaluate their impact on mortality or other outcomes of interest. Traditional analyses using baseline values of biomarkers (e.g., Cox proportional hazards or logistic regression models) do not take into account these dynamics. One approach to the evaluation of the impact of biomarkers on mortality rates is to use the Cox proportional hazards model with time-dependent covariates; this approach is used extensively in various applications and is available in all popular statistical packages. In such a model, the biomarker is considered a time-dependent covariate of the hazard rate and the corresponding regression parameter is estimated along with standard errors to make statistical inference on the direction and the significance of the effect of the biomarker on the outcome of interest (e.g., mortality). However, the choice of the analytic approach should not be governed exclusively by its simplicity or convenience of application. It is essential to consider whether the method gives meaningful and interpretable results relevant to the research agenda. In the particular case of biodemographic analyses, the Cox proportional hazards model with time-dependent covariates is not the best choice.

“Longitudinal studies of aging present special methodological challenges due to inherent characteristics of the data that need to be addressed in order to avoid biased inference. The challenges are related to the fact that the populations under study (aging individuals) experience substantial dropout rates related to death or poor health and often have co-morbid conditions related to the disease of interest. The standard assumption made in longitudinal analyses (although usually not explicitly mentioned in publications) is that dropout (e.g., death) is not associated with the outcome of interest. While this can be safely assumed in many general longitudinal studies (where, e.g., the main causes of dropout might be the administrative end of the study or moving out of the study area, which are presumably not related to the studied outcomes), the very nature of the longitudinal outcomes (e.g., measurements of some physiological biomarkers) analyzed in a longitudinal study of aging assumes that they are (at least hypothetically) related to the process of aging. Because the process of aging leads to the development of diseases and, eventually, death, in longitudinal studies of aging an assumption of non-association of the reason for dropout and the outcome of interest is, at best, risky, and usually is wrong. As an illustration, we found that the average trajectories of different physiological indices of individuals dying at earlier ages markedly deviate from those of long-lived individuals, both in the entire Framingham original cohort […] and also among carriers of specific alleles […] In such a situation, panel compositional changes due to attrition affect the averaging procedure and modify the averages in the total sample. Furthermore, biomarkers are subject to measurement error and random biological variability. They are usually collected intermittently at examination times which may be sparse and typically biomarkers are not observed at event times. It is well known in the statistical literature that ignoring measurement errors and biological variation in such variables and using their observed “raw” values as time-dependent covariates in a Cox regression model may lead to biased estimates and incorrect inferences […] Standard methods of survival analysis such as the Cox proportional hazards model (Cox 1972) with time-dependent covariates should be avoided in analyses of biomarkers measured with errors because they can lead to biased estimates.

“Statistical methods aimed at analyses of time-to-event data jointly with longitudinal measurements have become known in the mainstream biostatistical literature as “joint models for longitudinal and time-to-event data” (“survival” or “failure time” are often used interchangeably with “time-to-event”) or simply “joint models.” This is an active and fruitful area of biostatistics with an explosive growth in recent years. […] The standard joint model consists of two parts, the first representing the dynamics of longitudinal data (which is referred to as the “longitudinal sub-model”) and the second one modeling survival or, generally, time-to-event data (which is referred to as the “survival sub-model”). […] Numerous extensions of this basic model have appeared in the joint modeling literature in recent decades, providing great flexibility in applications to a wide range of practical problems. […] The standard parameterization of the joint model (11.2) assumes that the risk of the event at age t depends on the current “true” value of the longitudinal biomarker at this age. While this is a reasonable assumption in general, it may be argued that additional dynamic characteristics of the longitudinal trajectory can also play a role in the risk of death or onset of a disease. For example, if two individuals at the same age have exactly the same level of some biomarker at this age, but the trajectory for the first individual increases faster with age than that of the second one, then the first individual can have worse survival chances for subsequent years. […] Therefore, extensions of the basic parameterization of joint models allowing for dependence of the risk of an event on such dynamic characteristics of the longitudinal trajectory can provide additional opportunities for comprehensive analyses of relationships between the risks and longitudinal trajectories. Several authors have considered such extended models. […] joint models are computationally intensive and are sometimes prone to convergence problems [however such] models provide more efficient estimates of the effect of a covariate […] on the time-to-event outcome in the case in which there is […] an effect of the covariate on the longitudinal trajectory of a biomarker. This means that analyses of longitudinal and time-to-event data in joint models may require smaller sample sizes to achieve comparable statistical power with analyses based on time-to-event data alone (Chen et al. 2011).”

“To be useful as a tool for biodemographers and gerontologists who seek biological explanations for observed processes, models of longitudinal data should be based on realistic assumptions and reflect relevant knowledge accumulated in the field. An example is the shape of the risk functions. Epidemiological studies show that the conditional hazards of health and survival events considered as functions of risk factors often have U- or J-shapes […], so a model of aging-related changes should incorporate this information. In addition, risk variables, and, what is very important, their effects on the risks of corresponding health and survival events, experience aging-related changes and these can differ among individuals. […] An important class of models for joint analyses of longitudinal and time-to-event data incorporating a stochastic process for description of longitudinal measurements uses an epidemiologically-justified assumption of a quadratic hazard (i.e., U-shaped in general and J-shaped for variables that can take values only on one side of the U-curve) considered as a function of physiological variables. Quadratic hazard models have been developed and intensively applied in studies of human longitudinal data”.

“Various approaches to statistical model building and data analysis that incorporate unobserved heterogeneity are ubiquitous in different scientific disciplines. Unobserved heterogeneity in models of health and survival outcomes can arise because there may be relevant risk factors affecting an outcome of interest that are either unknown or not measured in the data. Frailty models introduce the concept of unobserved heterogeneity in survival analysis for time-to-event data. […] Individual age trajectories of biomarkers can differ due to various observed as well as unobserved (and unknown) factors and such individual differences propagate to differences in risks of related time-to-event outcomes such as the onset of a disease or death. […] The joint analysis of longitudinal and time-to-event data is the realm of a special area of biostatistics named “joint models for longitudinal and time-to-event data” or simply “joint models” […] Approaches that incorporate heterogeneity in populations through random variables with continuous distributions (as in the standard joint models and their extensions […]) assume that the risks of events and longitudinal trajectories follow similar patterns for all individuals in a population (e.g., that biomarkers change linearly with age for all individuals). Although such homogeneity in patterns can be justifiable for some applications, generally this is a rather strict assumption […] A population under study may consist of subpopulations with distinct patterns of longitudinal trajectories of biomarkers that can also have different effects on the time-to-event outcome in each subpopulation. When such subpopulations can be defined on the base of observed covariate(s), one can perform stratified analyses applying different models for each subpopulation. However, observed covariates may not capture the entire heterogeneity in the population in which case it may be useful to conceive of the population as consisting of latent subpopulations defined by unobserved characteristics. Special methodological approaches are necessary to accommodate such hidden heterogeneity. Within the joint modeling framework, a special class of models, joint latent class models, was developed to account for such heterogeneity […] The joint latent class model has three components. First, it is assumed that a population consists of a fixed number of (latent) subpopulations. The latent class indicator represents the latent class membership and the probability of belonging to the latent class is specified by a multinomial logistic regression function of observed covariates. It is assumed that individuals from different latent classes have different patterns of longitudinal trajectories of biomarkers and different risks of event. The key assumption of the model is conditional independence of the biomarker and the time-to-events given the latent classes. Then the class-specific models for the longitudinal and time-to-event outcomes constitute the second and third component of the model thus completing its specification. […] the latent class stochastic process model […] provides a useful tool for dealing with unobserved heterogeneity in joint analyses of longitudinal and time-to-event outcomes and taking into account hidden components of aging in their joint influence on health and longevity. This approach is also helpful for sensitivity analyses in applications of the original stochastic process model. We recommend starting the analyses with the original stochastic process model and estimating the model ignoring possible hidden heterogeneity in the population. Then the latent class stochastic process model can be applied to test hypotheses about the presence of hidden heterogeneity in the data in order to appropriately adjust the conclusions if a latent structure is revealed.”

The longitudinal genetic-demographic model (or the genetic-demographic model for longitudinal data) […] combines three sources of information in the likelihood function: (1) follow-up data on survival (or, generally, on some time-to-event) for genotyped individuals; (2) (cross-sectional) information on ages at biospecimen collection for genotyped individuals; and (3) follow-up data on survival for non-genotyped individuals. […] Such joint analyses of genotyped and non-genotyped individuals can result in substantial improvements in statistical power and accuracy of estimates compared to analyses of the genotyped subsample alone if the proportion of non-genotyped participants is large. Situations in which genetic information cannot be collected for all participants of longitudinal studies are not uncommon. They can arise for several reasons: (1) the longitudinal study may have started some time before genotyping was added to the study design so that some initially participating individuals dropped out of the study (i.e., died or were lost to follow-up) by the time of genetic data collection; (2) budget constraints prohibit obtaining genetic information for the entire sample; (3) some participants refuse to provide samples for genetic analyses. Nevertheless, even when genotyped individuals constitute a majority of the sample or the entire sample, application of such an approach is still beneficial […] The genetic stochastic process model […] adds a new dimension to genetic biodemographic analyses, combining information on longitudinal measurements of biomarkers available for participants of a longitudinal study with follow-up data and genetic information. Such joint analyses of different sources of information collected in both genotyped and non-genotyped individuals allow for more efficient use of the research potential of longitudinal data which otherwise remains underused when only genotyped individuals or only subsets of available information (e.g., only follow-up data on genotyped individuals) are involved in analyses. Similar to the longitudinal genetic-demographic model […], the benefits of combining data on genotyped and non-genotyped individuals in the genetic SPM come from the presence of common parameters describing characteristics of the model for genotyped and non-genotyped subsamples of the data. This takes into account the knowledge that the non-genotyped subsample is a mixture of carriers and non-carriers of the same alleles or genotypes represented in the genotyped subsample and applies the ideas of heterogeneity analyses […] When the non-genotyped subsample is substantially larger than the genotyped subsample, these joint analyses can lead to a noticeable increase in the power of statistical estimates of genetic parameters compared to estimates based only on information from the genotyped subsample. This approach is applicable not only to genetic data but to any discrete time-independent variable that is observed only for a subsample of individuals in a longitudinal study.

“Despite an existing tradition of interpreting differences in the shapes or parameters of the mortality rates (survival functions) resulting from the effects of exposure to different conditions or other interventions in terms of characteristics of individual aging, this practice has to be used with care. This is because such characteristics are difficult to interpret in terms of properties of external and internal processes affecting the chances of death. An important question then is: What kind of mortality model has to be developed to obtain parameters that are biologically interpretable? The purpose of this chapter is to describe an approach to mortality modeling that represents mortality rates in terms of parameters of physiological changes and declining health status accompanying the process of aging in humans. […] A traditional (demographic) description of changes in individual health/survival status is performed using a continuous-time random Markov process with a finite number of states, and age-dependent transition intensity functions (transitions rates). Transitions to the absorbing state are associated with death, and the corresponding transition intensity is a mortality rate. Although such a description characterizes connections between health and mortality, it does not allow for studying factors and mechanisms involved in the aging-related health decline. Numerous epidemiological studies provide compelling evidence that health transition rates are influenced by a number of factors. Some of them are fixed at the time of birth […]. Others experience stochastic changes over the life course […] The presence of such randomly changing influential factors violates the Markov assumption, and makes the description of aging-related changes in health status more complicated. […] The age dynamics of influential factors (e.g., physiological variables) in connection with mortality risks has been described using a stochastic process model of human mortality and aging […]. Recent extensions of this model have been used in analyses of longitudinal data on aging, health, and longevity, collected in the Framingham Heart Study […] This model and its extensions are described in terms of a Markov stochastic process satisfying a diffusion-type stochastic differential equation. The stochastic process is stopped at random times associated with individuals’ deaths. […] When an individual’s health status is taken into account, the coefficients of the stochastic differential equations become dependent on values of the jumping process. This dependence violates the Markov assumption and renders the conditional Gaussian property invalid. So the description of this (continuously changing) component of aging-related changes in the body also becomes more complicated. Since studying age trajectories of physiological states in connection with changes in health status and mortality would provide more realistic scenarios for analyses of available longitudinal data, it would be a good idea to find an appropriate mathematical description of the joint evolution of these interdependent processes in aging organisms. For this purpose, we propose a comprehensive model of human aging, health, and mortality in which the Markov assumption is fulfilled by a two-component stochastic process consisting of jumping and continuously changing processes. The jumping component is used to describe relatively fast changes in health status occurring at random times, and the continuous component describes relatively slow stochastic age-related changes of individual physiological states. […] The use of stochastic differential equations for random continuously changing covariates has been studied intensively in the analysis of longitudinal data […] Such a description is convenient since it captures the feedback mechanism typical of biological systems reflecting regular aging-related changes and takes into account the presence of random noise affecting individual trajectories. It also captures the dynamic connections between aging-related changes in health and physiological states, which are important in many applications.”

April 23, 2017 Posted by | Biology, Books, Demographics, Genetics, Mathematics, Statistics | Leave a comment

Promoting the unknown, a continuing series

April 21, 2017 Posted by | Music | Leave a comment

Biodemography of aging (III)

Latent class representation of the Grade of Membership model.
Singular value decomposition.
Affine space.
Lebesgue measure.
General linear position.

The links above are links to topics I looked up while reading the second half of the book. The first link is quite relevant to the book’s coverage as a comprehensive longitudinal Grade of Membership (-GoM) model is covered in chapter 17. Relatedly, chapter 18 covers linear latent structure (-LLS) models, and as observed in the book LLS is a generalization of GoM. As should be obvious from the nature of the links some of the stuff included in the second half of the text is highly technical, and I’ll readily admit I was not fully able to understand all the details included in the coverage of chapters 17 and 18 in particular. On account of the technical nature of the coverage in Part 2 I’m not sure I’ll cover the second half of the book in much detail, though I probably shall devote at least one more post to some of those topics, as they were quite interesting even if some of the details were difficult to follow.

I have almost finished the book at this point, and I have already decided to both give the book five stars and include it on my list of favorite books on goodreads; it’s really well written, and it provides consistently highly detailed coverage of very high quality. As I also noted in the first post about the book the authors have given readability aspects some thought, and I am sure most readers would learn quite a bit from this text even if they were to skip some of the more technical chapters. The main body of Part 2 of the book, the subtitle of which is ‘Statistical Modeling of Aging, Health, and Longevity’, is however probably in general not worth the effort of reading unless you have a solid background in statistics.

This post includes some observations and quotes from the last chapters of the book’s Part 1.

“The proportion of older adults in the U.S. population is growing. This raises important questions about the increasing prevalence of aging-related diseases, multimorbidity issues, and disability among the elderly population. […] In 2009, 46.3 million people were covered by Medicare: 38.7 million of them were aged 65 years and older, and 7.6 million were disabled […]. By 2031, when the baby-boomer generation will be completely enrolled, Medicare is expected to reach 77 million individuals […]. Because the Medicare program covers 95 % of the nation’s aged population […], the prediction of future Medicare costs based on these data can be an important source of health care planning.”

“Three essential components (which could be also referred as sub-models) need to be developed to construct a modern model of forecasting of population health and associated medical costs: (i) a model of medical cost projections conditional on each health state in the model, (ii) health state projections, and (iii) a description of the distribution of initial health states of a cohort to be projected […] In making medical cost projections, two major effects should be taken into account: the dynamics of the medical costs during the time periods comprising the date of onset of chronic diseases and the increase of medical costs during the last years of life. In this chapter, we investigate and model the first of these two effects. […] the approach developed in this chapter generalizes the approach known as “life tables with covariates” […], resulting in a new family of forecasting models with covariates such as comorbidity indexes or medical costs. In sum, this chapter develops a model of the relationships between individual cost trajectories following the onset of aging-related chronic diseases. […] The underlying methodological idea is to aggregate the health state information into a single (or several) covariate(s) that can be determinative in predicting the risk of a health event (e.g., disease incidence) and whose dynamics could be represented by the model assumptions. An advantage of such an approach is its substantial reduction of the degrees of freedom compared with existing forecasting models  (e.g., the FEM model, Goldman and RAND Corporation 2004). […] We found that the time patterns of medical cost trajectories were similar for all diseases considered and can be described in terms of four components having the meanings of (i) the pre-diagnosis cost associated with initial comorbidity represented by medical expenditures, (ii) the cost peak associated with the onset of each disease, (iii) the decline/reduction in medical expenditures after the disease onset, and (iv) the difference between post- and pre-diagnosis cost levels associated with an acquired comorbidity. The description of the trajectories was formalized by a model which explicitly involves four parameters reflecting these four components.”

As I noted earlier in my coverage of the book, I don’t think the model above fully captures all relevant cost contributions of the diseases included, as the follow-up period was too short to capture all relevant costs to be included in the part iv model component. This is definitely a problem in the context of diabetes. But then again nothing in theory stops people from combining the model above with other models which are better at dealing with the excess costs associated with long-term complications of chronic diseases, and the model results were intriguing even if the model likely underperforms in a few specific disease contexts.

Moving on…

“Models of medical cost projections usually are based on regression models estimated with the majority of independent predictors describing demographic status of the individual, patient’s health state, and level of functional limitations, as well as their interactions […]. If the health states needs to be described by a number of simultaneously manifested diseases, then detailed stratification over the categorized variables or use of multivariate regression models allows for a better description of the health states. However, it can result in an abundance of model parameters to be estimated. One way to overcome these difficulties is to use an approach in which the model components are demographically-based aggregated characteristics that mimic the effects of specific states. The model developed in this chapter is an example of such an approach: the use of a comorbidity index rather than of a set of correlated categorical regressor variables to represent the health state allows for an essential reduction in the degrees of freedom of the problem.”

“Unlike mortality, the onset time of chronic disease is difficult to define with high precision due to the large variety of disease-specific criteria for onset/incident case identification […] there is always some arbitrariness in defining the date of chronic disease onset, and a unified definition of date of onset is necessary for population studies with a long-term follow-up.”

“Individual age trajectories of physiological indices are the product of a complicated interplay among genetic and non-genetic (environmental, behavioral, stochastic) factors that influence the human body during the course of aging. Accordingly, they may differ substantially among individuals in a cohort. Despite this fact, the average age trajectories for the same index follow remarkable regularities. […] some indices tend to change monotonically with age: the level of blood glucose (BG) increases almost monotonically; pulse pressure (PP) increases from age 40 until age 85, then levels off and shows a tendency to decline only at later ages. The age trajectories of other indices are non-monotonic: they tend to increase first and then decline. Body mass index (BMI) increases up to about age 70 and then declines, diastolic blood pressure (DBP) increases until age 55–60 and then declines, systolic blood pressure (SBP) increases until age 75 and then declines, serum cholesterol (SCH) increases until age 50 in males and age 70 in females and then declines, ventricular rate (VR) increases until age 55 in males and age 45 in females and then declines. With small variations, these general patterns are similar in males and females. The shapes of the age-trajectories of the physiological variables also appear to be similar for different genotypes. […] The effects of these physiological indices on mortality risk were studied in Yashin et al. (2006), who found that the effects are gender and age specific. They also found that the dynamic properties of the individual age trajectories of physiological indices may differ dramatically from one individual to the next.”

“An increase in the mortality rate with age is traditionally associated with the process of aging. This influence is mediated by aging-associated changes in thousands of biological and physiological variables, some of which have been measured in aging studies. The fact that the age trajectories of some of these variables differ among individuals with short and long life spans and healthy life spans indicates that dynamic properties of the indices affect life history traits. Our analyses of the FHS data clearly demonstrate that the values of physiological indices at age 40 are significant contributors both to life span and healthy life span […] suggesting that normalizing these variables around age 40 is important for preventing age-associated morbidity and mortality later in life. […] results [also] suggest that keeping physiological indices stable over the years of life could be as important as their normalizing around age 40.”

“The results […] indicate that, in the quest of identifying longevity genes, it may be important to look for candidate genes with pleiotropic effects on more than one dynamic characteristic of the age-trajectory of a physiological variable, such as genes that may influence both the initial value of a trait (intercept) and the rates of its changes over age (slopes). […] Our results indicate that the dynamic characteristics of age-related changes in physiological variables are important predictors of morbidity and mortality risks in aging individuals. […] We showed that the initial value (intercept), the rate of changes (slope), and the variability of a physiological index, in the age interval 40–60 years, significantly influenced both mortality risk and onset of unhealthy life at ages 60+ in our analyses of the Framingham Heart Study data. That is, these dynamic characteristics may serve as good predictors of late life morbidity and mortality risks. The results also suggest that physiological changes taking place in the organism in middle life may affect longevity through promoting or preventing diseases of old age. For non-monotonically changing indices, we found that having a later age at the peak value of the index […], a lower peak value […], a slower rate of decline in the index at older ages […], and less variability in the index over time, can be beneficial for longevity. Also, the dynamic characteristics of the physiological indices were, overall, associated with mortality risk more significantly than with onset of unhealthy life.”

“Decades of studies of candidate genes show that they are not linked to aging-related traits in a straightforward manner […]. Recent genome-wide association studies (GWAS) have reached fundamentally the same conclusion by showing that the traits in late life likely are controlled by a relatively large number of common genetic variants […]. Further, GWAS often show that the detected associations are of tiny effect […] the weak effect of genes on traits in late life can be not only because they confer small risks having small penetrance but because they confer large risks but in a complex fashion […] In this chapter, we consider several examples of complex modes of gene actions, including genetic tradeoffs, antagonistic genetic effects on the same traits at different ages, and variable genetic effects on lifespan. The analyses focus on the APOE common polymorphism. […] The analyses reported in this chapter suggest that the e4 allele can be protective against cancer with a more pronounced role in men. This protective effect is more characteristic of cancers at older ages and it holds in both the parental and offspring generations of the FHS participants. Unlike cancer, the effect of the e4 allele on risks of CVD is more pronounced in women. […] [The] results […] explicitly show that the same allele can change its role on risks of CVD in an antagonistic fashion from detrimental in women with onsets at younger ages to protective in women with onsets at older ages. […] e4 allele carriers have worse survival compared to non-e4 carriers in each cohort. […] Sex stratification shows sexual dimorphism in the effect of the e4 allele on survival […] with the e4 female carriers, particularly, being more exposed to worse survival. […] The results of these analyses provide two important insights into the role of genes in lifespan. First, they provide evidence on the key role of aging-related processes in genetic susceptibility to lifespan. For example, taking into account the specifics of aging-related processes gains 18 % in estimates of the RRs and five orders of magnitude in significance in the same sample of women […] without additional investments in increasing sample sizes and new genotyping. The second is that a detailed study of the role of aging-related processes in estimates of the effects of genes on lifespan (and healthspan) helps in detecting more homogeneous [high risk] sub-samples”.

“The aging of populations in developed countries requires effective strategies to extend healthspan. A promising solution could be to yield insights into the genetic predispositions for endophenotypes, diseases, well-being, and survival. It was thought that genome-wide association studies (GWAS) would be a major breakthrough in this endeavor. Various genetic association studies including GWAS assume that there should be a deterministic (unconditional) genetic component in such complex phenotypes. However, the idea of unconditional contributions of genes to these phenotypes faces serious difficulties which stem from the lack of direct evolutionary selection against or in favor of such phenotypes. In fact, evolutionary constraints imply that genes should be linked to age-related phenotypes in a complex manner through different mechanisms specific for given periods of life. Accordingly, the linkage between genes and these traits should be strongly modulated by age-related processes in a changing environment, i.e., by the individuals’ life course. The inherent sensitivity of genetic mechanisms of complex health traits to the life course will be a key concern as long as genetic discoveries continue to be aimed at improving human health.”

“Despite the common understanding that age is a risk factor of not just one but a large portion of human diseases in late life, each specific disease is typically considered as a stand-alone trait. Independence of diseases was a plausible hypothesis in the era of infectious diseases caused by different strains of microbes. Unlike those diseases, the exact etiology and precursors of diseases in late life are still elusive. It is clear, however, that the origin of these diseases differs from that of infectious diseases and that age-related diseases reflect a complicated interplay among ontogenetic changes, senescence processes, and damages from exposures to environmental hazards. Studies of the determinants of diseases in late life provide insights into a number of risk factors, apart from age, that are common for the development of many health pathologies. The presence of such common risk factors makes chronic diseases and hence risks of their occurrence interdependent. This means that the results of many calculations using the assumption of disease independence should be used with care. Chapter 4 argued that disregarding potential dependence among diseases may seriously bias estimates of potential gains in life expectancy attributable to the control or elimination of a specific disease and that the results of the process of coping with a specific disease will depend on the disease elimination strategy, which may affect mortality risks from other diseases.”

April 17, 2017 Posted by | Biology, Books, Cancer/oncology, Demographics, Economics, Epidemiology, Genetics, Medicine, Statistics | Leave a comment

Quotes

i. “Self-love is often rather arrogant than blind; it does not hide our faults from ourselves, but persuades us that they escape the notice of others.” (Samuel Johnson)

ii. “So much are the modes of excellence settled by time and place, that men may be heard boasting in one street of that which they would anxiously conceal in another.” (-ll-)

iii. “The greatest of faults, I should say, is to be conscious of none.” (Thomas Carlyle)

iv. “Like most of those who study history, he learned from the mistakes of the past how to make new ones.” (Alan John Percivale Taylor)

v. “A method of reasoning may lead to conclusions which are invariably true, even though it start from false premises.” (Francesco Maria Zanotti)

vi. “We are much harder on people who betray us in small ways than on people who betray others in great ones.” (Rochefoucauld)

vii. “Most people are good only so long as they believe others so.” (Friedrich Hebbel)

viii. “Men are more ready to offend one who desires to be beloved than one who wishes to be feared.” (Niccolò Machiavelli)

ix. “Some have been thought brave because they were afraid to run away.” (Thomas Fuller)

x. “Calumny is like counterfeit money: many people who would not coin it circulate it without qualms.” (Diane De Poitiers)

xi. “Let us leave the labels to those who have little else wherewith to cover their nakedness.” (Walter Sickert)

xii. “…there are few truths important enough to justify paining and reproving others for not knowing them…” (Montesquieu)

xiii. “To make astute people believe one is what one is not is, in most cases, harder than actually to become what one wishes to appear.” (Georg Christoph Lichtenberg)

xiv. “It is a trick among the dishonest to offer sacrifices that are not needed, or not possible, to avoid making those that are required.” (Ivan Goncharov)

xv. “It is seldom that the miserable can help regarding their misery as a wrong inflicted by those who are less miserable” (George Eliot)

xvi. “Thousands upon thousands are yearly brought into a state of real poverty by their great anxiety not to be thought poor.” (William Cobbett)

xvii. “The woman whose behavior indicates that she will make a scene if she is told the truth asks to be deceived.” (Elizabeth Jenkins)

xviii. “My business is to teach my aspirations to confirm themselves to facts, not to try and make facts harmonize with my aspirations.” (Thomas Henry Huxley)

xix. “The art of doing mathematics consists in finding that special case which contains all the germs of generality.” (David Hilbert)

xx. “”Obvious” is the most dangerous word in mathematics.” (Eric Temple Bell)

April 15, 2017 Posted by | Quotes/aphorisms | Leave a comment

Words

Lately I’ve been reading some of George MacDonald Fraser’s Flashman books, which have been quite enjoyable reads in general; I’m reading the books in the order in which the actions in the books supposedly took place, not in the order in which the books were published, and a large number of the words included below are words I encountered in the first three of the books I read (i.e. FlashmanRoyal Flash, and Flashman’s Lady); I decided the post already at that point included a large number of words (the post includes roughly 120 words), so I saw no need to add additional words from the other books in the series in this post as well. I have reviewed a few of the Flashman books I’ve read on goodreads here, here, and here.

Havildar, gimbal, quorum, unmannerly, tribulation, thalassophobia, kiln, sheave, grody, contemn, arcanum, deloping, poulterer, fossorial, catamount, guttersnipe, nabob, frond, matelot, jetty.

Sangar, palliasse, junoesque, cornet, bugle, fettle, toady, thong, trollop, sepoy, wattle, hardtack, snuffle, chunter, ghillie, barker, trousseau, simper, madcap, ramrod.

Welt, landau, declaim, burgomaster, scupper, windlass, maunder, sniffy, sirdar, randy, dowager, toffs, pug, curvet, pish, scriveners, hoyden, manikin, lecher/lechery, busby.

Ruck, leery, ninny, shillyshally, mincing, ringlet, covey, pip, munshi, risaldar, maidan, palankeen/palanquin, forbye, feringhee, cantonment, puggaree, pannikin, dollymop, snook, cordage.

Suet/suety, strumpet, kenspeckle, magsman, scrag, chandler, prigger, chivvy, décolleté, dundrearies, assignation, bruit, purblind, trull, slatterncoffle, doggo, cellarette, cummerbund, agley.

Sampan, wideawake, popsycollation, déshabillé, pinnace, pennant, murk, sprig, linstock, tassel, bangle, trammel, prau, shellback, shako, clobbertaffrail, crinolinetaffeta, commonalty.

April 15, 2017 Posted by | Books, language | Leave a comment

Quotes

i. “No man is rich enough to buy back his past.” (Oscar Wilde)

ii. “There is a luxury in self-reproach. When we blame ourselves we feel that no one else has a right to blame us.” (-ll-)

iii. “Each new generation asks – What is the meaning of life? A more fertile way of putting the question would be – Why does man need a meaning to life?” (Peter Wessel Zapffe)

iv. “One man’s constant is another man’s variable.” (Alan Perlis)

v. “All scientific work is incomplete – whether it be observational or experimental. All scientific work is liable to be upset or modified by advancing knowledge. That does not confer upon us a freedom to ignore the knowledge we already have, or to postpone the action that it appears to demand at a given time.” (Austin Bradford Hill)

vi. “Most women set out to try to change a man, and when they have changed him they do not like him.” (Marlene Dietrich)

vii. “We speak with our lips to explain, with our throats to convince.” (Malcolm de Chazal)

viii. “Those who do not complain are never pitied.” (Jane Austen)

ix. “It is an aspect of all happiness to suppose that we deserve it.” (Joseph Joubert)

x. “Almost all absurdity of conduct arises from the imitation of those whom we cannot resemble.” (Samuel Johnson)

xi. “Nothing so much prevents our being natural as the desire to seem so.” (Rochefoucauld)

xii. “It is harder to hide feelings we have than to feign those we lack.” (-ll-)

xiii. “Almost all our faults are more pardonable than the methods we resort to to hide them.” (-ll-)

xiv. “Fanaticism consists of redoubling your efforts when you have forgotten your aim.” (George Santayana)

xv. “There is nothing that fear or hope does not make men believe.” (Vauvenargues)

xvi. “There is no rule more invariable than that we are paid for our suspicions by finding what we suspected.” (Henry David Thoreau)

xvii. “It is hard to believe that a man is telling the truth when you know that you would lie if you were in his place.” (H.L. Mencken)

xviii. “Conscience is thoroughly well bred and soon leaves off talking to those who do not wish to hear it.” (Samuel Butler)

xix. “History is not written as it was experienced, nor should it be. The inhabitants of the past know better than we do what it was like to live there, but they were not well placed, most of them, to understand what was happening to them and why.” (Tony Judt)

xx. “Stability is much underappreciated, especially by those who enjoy its benefits.” (Curtis Yarvin)

April 5, 2017 Posted by | Quotes/aphorisms | Leave a comment